AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancerDavid S. Hong, A. Robert MacLeod, Nathan Fowler et al.|Science Translational Medicine|2015Cited by 438
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J. Reilley, David S. Hong, Patricia McCoon et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 286
High INHBB expression in colorectal cancer is associated with poor prognosis and drives malignant phenotypes in tumor cellsHuiyan Chen, Hu Zhao, Yao Wu et al.|Biology Direct|2026Cited by 0